FDA’s New China Director Looks To Strengthen CFDA Ties
This article was originally published in PharmAsia News
August saw a change in the US FDA’s point person for China, as long-term FDA China director Chris Hickey left for a positon with Pfizer and Leigh Verbois took the charge with a mission to further develop strong ties with the China FDA amid the Chinese regulator’s hectic efforts to jumpstart regulatory reforms.
You may also be interested in...
Which drug candidates represent hope, and which hype? The Scrip team examine the COVID-19 pipeline, lessons from China, and some long term impacts on the sector.
China insists there is no double standard and won’t tolerate any quality issues in its centralized procurement process.
After winning a major procurement contract, BeiGene now may need to find an alternative manufacturing site for Celgene's Abraxane to supply China.